FIELD: chemistry.
SUBSTANCE: method of increasing neratinib oral absorption incudes neratinib administering to a patient in the form of maleate salt, where the neratinib maleate salt is a crystalline monohydrate of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide maleate (Form II). The invention also relates to a method for cancer treatment including neratinib administering to a patient in the form maleate salt (Form II).
EFFECT: increased oral absorption and cancer treatment based on the use of a crystal form of neratinib maleate salt.
7 cl, 8 dwg, 11 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| -N-{4-[3-CHLOR-4-(2-PYRIDINYLMETHOXY)ANILINO]-3-CYANO-7-ETHOXY-6-QUINOLINYL}-4-(DIMETHYLAMINO)-2-BUTENAMIDE MALEATE SALTS AND THEIR CRYSTALLINE FORMS | 2008 |
|
RU2463300C2 |
| MALEATE SALTS OF (E)-N-{4-[3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO]-3-CYANO-7-ETHOXY-6-QUINOLINYL}-4-(DIMETHYLAMINO)-2-BUTENAMIDE AND THEIR CRYSTALLINE FORMS | 2017 |
|
RU2807142C1 |
| 3-CYANOQUINOLIMES AS INHIBITORS OF EGF-R AND HER2 KINASES | 2002 |
|
RU2309150C2 |
| ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE | 2009 |
|
RU2492860C2 |
| KINASE INHIBITORS, PRODRUG FORMS THEREOF AND USE THEREOF IN THERAPY | 2010 |
|
RU2568639C2 |
| SUBSTITUTED 3-CYANOQUINOLINES | 1998 |
|
RU2202551C2 |
| PHARMACEUTICALLY ACCEPTABLE SALT (E)-N-[4-[[3-CHLORO-4-(2-PYRIDYLMETHOXY) PHENYL] AMINO] -3-CYANO-7-ETHOXY-6-QUINOLYL] -3-[(2R)- 1- METHYLPYRROLIDIN-2-YL] PROP-2-ENAMIDE, METHOD FOR PRODUCTION AND USE THEREOF IN TREATING CANCER | 2012 |
|
RU2583056C2 |
| SYTHESIS OF 4-AMINO-2-BUTENOYLCHLORIDES AND THEIR USE IN MAKING 3-CYANOQUINOLINES | 2004 |
|
RU2345984C2 |
| CRYSTALLINE FORMS AND TWO SOLVATE FORMS OF LACTIC ACID SALTS 4-AMINO-5-FLUORINE-3-[5-(4-METHYLPIPERAZIN-1-YL)-1-H-BENZIMIDAZOL-2-YL]QUINOLINE-2(1H)ONE | 2009 |
|
RU2497820C2 |
| 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE OF SAID COMPOUND | 2015 |
|
RU2704129C2 |
